|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-12-5
|
|
pubmed:abstractText |
In breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1340-6868
|
|
pubmed:author |
pubmed-author:AkiyamaFutoshiF,
pubmed-author:FurukawaKeikoK,
pubmed-author:FurukawaKiyonoriK,
pubmed-author:HatakeKiyohikoK,
pubmed-author:HorikoshiNoboruN,
pubmed-author:ItoYoshinoriY,
pubmed-author:KasumiFujioF,
pubmed-author:MizunumaNobuyukiN,
pubmed-author:SakamotoGoiG,
pubmed-author:SawakiMasatakaM,
pubmed-author:TajiriTakashiT,
pubmed-author:TakahashiShunjiS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
329-33
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17146157-Antibodies, Monoclonal,
pubmed-meshheading:17146157-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17146157-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17146157-Breast Neoplasms,
pubmed-meshheading:17146157-Drug Administration Schedule,
pubmed-meshheading:17146157-Female,
pubmed-meshheading:17146157-Humans,
pubmed-meshheading:17146157-Infusions, Intravenous,
pubmed-meshheading:17146157-Neutropenia,
pubmed-meshheading:17146157-Paclitaxel,
pubmed-meshheading:17146157-Peripheral Nervous System Diseases,
pubmed-meshheading:17146157-Receptor, erbB-2,
pubmed-meshheading:17146157-Retrospective Studies,
pubmed-meshheading:17146157-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
|
|
pubmed:affiliation |
Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan. keikofuru@triton.ocn.ne.jp
|
|
pubmed:publicationType |
Journal Article
|
